Abstract：
This review serves to compare contemporary clinical practice recommendations for the management of heart failure (HF), as codified in the 2021 European Society of Cardiology (ESC) guideline, the 2022 American College of Cardiology (ACC)/American Heart Association (AHA)/Heart Failure Society of America (HFSA) guideline, and the 2023 focused update of the 2021 ESC document. Overall, these guidelines aim to solidify significant advances throughout the HF continuum since the publication of previous full guideline iterations (2013 and 2016 for the ACC/AHA and ESC, respectively). All guidelines provide new recommendations for an increasingly complex landscape of HF care, with focus on primary HF prevention, HF stages, rapid initiation and optimization of evidence-based pharmacotherapies, overlapping cardiac and noncardiac comorbidities, device-based therapies, and management pathways for special groups of patients, including those with cardiac amyloidosis. Importantly, the ACC/AHA/HFSA document features special emphasis on HF risk prediction and screening, cost/value, social determinants of health, and health care disparities. The review discusses major similarities and differences between these recent guidelines and guideline updates, as well as their potential downstream implications for clinical care.
摘要：
这篇综述用于比较心力衰竭（HF）管理的当代临床实践建议，正如2021年欧洲心脏病学会(ESC)指南所编纂的那样，2022年美国心脏病学会（ACC）/美国心脏协会（AHA）/美国心力衰竭学会（HFSA）指南，和2023年重点更新的2021年ESC文件。总的来说,这些指南旨在巩固自先前的完整指南迭代（2013年和2016年针对ACC/AHA和ESC，分别)。所有指南都为日益复杂的HF护理提供了新的建议，重点是初级HF预防，HF阶段，快速启动和优化循证药物治疗，重叠的心脏和非心脏合并症，基于设备的疗法，以及针对特殊患者群体的管理途径，包括那些有心脏淀粉样变性的患者.重要的是,ACC/AHA/HFSA文件特别强调HF风险预测和筛查，成本/价值，健康的社会决定因素，和医疗保健差距。审查讨论了这些最新指南和指南更新之间的主要相似之处和不同之处，以及它们对临床护理的潜在下游影响。
